0001209191-17-058480.txt : 20171031
0001209191-17-058480.hdr.sgml : 20171031
20171031181642
ACCESSION NUMBER: 0001209191-17-058480
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171027
FILED AS OF DATE: 20171031
DATE AS OF CHANGE: 20171031
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 171166871
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-10-27
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP\Chief Commercial Officer
Common Stock
2017-10-27
4
S
0
4165
141.41
D
116952
D
Common Stock
2017-10-27
4
M
0
2125
96.87
A
119077
D
Common Stock
2017-10-27
4
S
0
2125
149.00
D
116952
D
Common Stock
2017-10-31
4
S
0
11617
142.18
D
105335
D
Common Stock
2017-10-31
4
S
0
5600
143.54
D
99735
D
Common Stock
2017-10-31
4
S
0
25999
144.54
D
73736
D
Common Stock
2017-10-31
4
S
0
17501
145.34
D
56235
D
Common Stock
2017-10-31
4
S
0
7783
146.61
D
48452
D
Common Stock
2017-10-31
4
S
0
5000
147.87
D
43452
D
Common Stock
2017-10-31
4
S
0
1000
148.54
D
42452
D
Common Stock
2017-10-31
4
S
0
500
149.34
D
41952
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
96.87
2017-10-27
4
M
0
2125
0.00
D
2024-07-14
Common Stock
2125
6375
D
Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $142.18 (range $141.83 to $142.74).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $143.54 (range $143.03 to $144.02).
Open market sales reported on this line occurred at a weighted average price of $144.54 (range $144.04 to $145.01).
Open market sales reported on this line occurred at a weighted average price of $145.34 (range $145.05 to $145.87).
Open market sales reported on this line occurred at a weighted average price of $146.61 (range $146.20 to $147.18).
Open market sales reported on this line occurred at a weighted average price of $147.87 (range $147.22 to $148.20).
Open market sales reported on this line occurred at a weighted average price of $148.54 (range $148.25 to $149.18).
The option vests in 16 quarterly installments from 7/15/2014.
/s/ Omar White, Attorney-in-Fact
2017-10-31